Horizon Europe is the EU’s key funding programme for research and innovation. Read more about the Horizon Europe programme here.
This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of Horizon Europe destination 3 “Tackling diseases and reducing disease burden”.
This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination 3 “Tackling diseases and reducing disease burden”. To that end, proposals under this topic should aim for delivering results that are directed, tailored towards and contributing to most of the following expected outcomes:
- The scientific and clinical communities make effective use of state-of-the-art information, data, technologies, tools and best practices to better understand the condition, underpinning the development of diagnostics, therapeutics and/or preventive strategies.
- The scientific and clinical community exchange data, knowledge and best practices, thereby strengthening their collaboration and building knowledge and care networks in Europe and beyond.
- The scientific and clinical community make wide use of newly established and where relevant open access databases and/or integrate them with existing infrastructures for storage and sharing of collected data according to FAIR 174 principles, thereby encouraging further use of the data.
- Policymakers and funders are informed of the research advances made and consider further support in light of the sustainability of the studies.
- Patients and caregivers are constructively engaged with the research, which also caters for their needs.
- Health professionals have access to and use improved clinical guidelines on diagnosis and/or treatment of the condition.
To be eligible for funding, applicants must be established in one of the following countries:
- the Member States of the European Union, including their outermost regions;
- the Overseas Countries and Territories (OCTs) linked to the Member States;
- countries associated to Horizon Europe;
- low- and middle-income countries
See the full list in the General Annexes.
The following exceptions apply:
In recognition of the opening of the US National Institutes of Health’s programmes to European researchers, any legal entity established in the United States of America is eligible to receive Union funding.
Unless otherwise provided for in the specific call conditions, only legal entities forming a consortium are eligible to participate in actions provided that the consortium includes, as beneficiaries, three legal entities independent from each other and each established in a different country as follows:
- at least one independent legal entity established in a Member State; and
- at least two other independent legal entities, each established in different Member States or Associated Countries.
The total indicative budget for the topic is EUR 25.00 million.
The Commission estimates that an EU contribution of between EUR 6.00 and 7.00 million would allow these outcomes to be addressed appropriately.